Arthritis CD56+ NK Cells

About Arthritis CD56+ NK Cells

Arthritis CD56+ NK Cells for Immunology Research

Arthritis CD56+ NK Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with arthritis. These CD56+ CD3− natural killer cells reflect disease-associated immune alterations and support studies of immune surveillance, inflammation, and cytotoxicity.

Which Type of Arthritis Do You Need?

“Arthritis” spans conditions with fundamentally different mechanisms, and NK cell biology differs across them. Specifying the subtype matters more than the cell count:

• Autoimmune inflammatory arthritis — rheumatoid arthritis and psoriatic arthritis, where NK cells accumulate in synovium and contribute to cytokine-driven inflammation
• Degenerative arthritis — osteoarthritis, driven by cartilage breakdown and low-grade rather than autoimmune inflammation
• Crystal arthropathy — gout, where monosodium urate crystals trigger NLRP3 inflammasome and IL-1β-mediated innate activation
• Connective tissue disease with joint involvement — systemic lupus erythematosus, Sjögren’s syndrome, and scleroderma

If your protocol calls for a broad arthritis cohort rather than a single diagnosis, we can assemble a mixed set with each donor’s specific subtype annotated — often the better design for method development, where you want the full analyte range rather than one mechanism.

NK Cells in Arthritis

• Synovial NK accumulation — NK cells are enriched in inflamed joints relative to blood, with a distinct CD56-bright profile
• Altered cytotoxic capacity and activating/inhibitory receptor balance
• Cytokine production — IFN-γ and TNF-α contributing to the inflammatory milieu
• KIR/HLA associations reported in several inflammatory arthritis subtypes
• Treatment effects — biologic therapy measurably alters NK phenotype, so treatment status matters

Donor Stratification Available

• Arthritis subtype — specific diagnosis annotated per donor
• Disease activity — DAS28, CRP, ESR where recorded
• Serostatus — rheumatoid factor and anti-CCP for inflammatory arthritis donors
• Treatment status — treatment-naive, conventional DMARD, or biologic-treated
• Paired specimens — matched synovial fluid, serum, or PBMC from the same donor
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD56+ enriched NK cells
• Isolated from clinically diagnosed arthritis donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of arthritis, including subtype
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• Investigation of NK cell phenotypes and function in arthritis
• Comparative studies across arthritis subtypes
• Cytotoxicity, degranulation, and immune exhaustion assays
• CD56-bright vs CD56-dim subset analysis
• Single-cell analysis and disease mechanism studies
• Biomarker identification and preclinical immunotherapy development

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Arthritis CD56+ NK Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD56+ NK cells collection.